Combining RNA interference and kinase inhibitors against cell signalling components involved in cancer

BMC Cancer

Volumn 5, Issue , 2005, Pages

  O'Grady, Michael ^a   Raha, Debasish ^a   Hanson, Bonnie J ^a   Bunting, Michaeline ^a   Hanson, George T ^a  

^a INVITROGEN CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; AG 183; BETA LACTAMASE; CELL PROTEIN; CL 387785; COMPLEMENTARY RNA; DOUBLE STRANDED RNA; DSRNAI STEALTH; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; IMATINIB; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MONOCLONAL ANTIBODY; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; OLIGONUCLEOTIDE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SMALL INTERFERING RNA; SMALL MOLECULE INHIBITOR; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; 1,3 BUTADIENE DERIVATIVE; ANTISENSE OLIGONUCLEOTIDE; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR; NITRILE; QUINAZOLINE DERIVATIVE; TYRPHOSTIN;

ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; IMMUNOCYTOCHEMISTRY; MALIGNANT TRANSFORMATION; MOLECULAR GENETICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UTERINE CERVIX CANCER; CHEMISTRY; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; METABOLISM; NEOPLASM; PHOSPHORYLATION; REPORTER GENE;

ANTIBODIES, MONOCLONAL; BETA-LACTAMASES; BUTADIENES; CELL DIFFERENTIATION; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITORY CONCENTRATION 50; MAP KINASE KINASE 1; NEOPLASMS; NITRILES; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHORYLATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; TRANSFECTION; TYRPHOSTINS;

EID: 27644590850     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-5-125     Document Type: Article

References (34)

1. Collett M, Erikson R: Protein kinase activity associated with the avian sarcoma virus src gene product. Proc. Natl Acad. Sci 1978, 75:2021-2024.
2. Atalay G, Cardaso F, Awada A, Piccart MJ: Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Annals of Oncology 2003, 14:1346-1363.
3. Cohen P: Protein kinases - the major drug targets of the twenty-first century? Nature Rev. Drug Discov. 2002, 1:309-315.
4. Levitzki A: Tyrosine kinases as targets for cancer therapy. European Journal of Cancer 2002, 38:S11-S18.
5. Tiseo M, Loprevite M, Ardizzoni A: Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer. Curr. Med. Chem.-Anti-Cancer Agents 2004, 4:139-148.
6. Perez-Soler R: HER1/EGFR Targeting: Refining the Strategy. The Oncologist 2004, 9:58-67.
7. Levitzki A: EGF receptor as a therapeutic target. Lung Cancer 2003, 41:S9-S14.
8. Hidaki H, Inagaki M., Kawamoto S., & Sasaki Y: Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry 1984, 23:5036-5041.
9. Muhsin M, Graham J., Kirkpatrick P: Hot Drugs 2004: Cancer. Nature Rev. Drug Discov. 2004, 3:S6-S10.
10. Gough NR, Adler EM, Ray B: Focus Issue: Targeting Signaling Pathways for Drug Discovery. Science's STKE 2004:eg5.
11. Smith JK, Mamoon NM, Duhe RJ: Emerging Roles of Targeted Small Molecule Protein-Tyrosine Kinase Inhibitors in Cancer Therapy. Oncology Research 2004, 14:175-225.
12. Sebolt-Leopold JS: MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors. Curr Pharm Des 2004, 10:1907-14.
13. Garcia-Echeverria C, Fabbro D: Therapeutically targeted anticancer agents: inhibitors of receptor tyrosine kinases. Mini Rev Med Chem. 2004, 4:273-283.
14. Azam M, Latek R, Daley G: Mechanisms of autoinhibition and STI-571/Imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003, 112:831-843.
15. Pao W, Miller V, Politi K, Riely G, Somwar R, Zakowski M, Kris M, Varmus H: Acquired resistance of lung adenocarcinomas to gefitinib or elotinib is associated with a second mutation in the EGFR kinase domain. PLoS Medicine 2005, 2:225-234.
16. Daub H, Specht S, Ullrich A: Strategies to overcome resistance to targeted protein kinase inhibitors. Nature Rev. Drug Discov. 2005, 3:1001-1010.
17. Bain J, McLauchlan H, Elliott M, Cohen P: The specificities of protein kinase inhibitors: an update. Biochem J 2003, 371:199-204.
18. Sykes J: Some properties of a new epithelial cell line of human origin. J. Nat Cancer Inst. 1970, 66:107-112.
19. Zlokarnik G, Knapp TE, Mere L, Burres N, Feng L, Whitney M, Roemer K, Tsien RY.: Quantitation of transcription and clonal selection of single living cells with beta-lactamase as reporter. Science 1998, 279:84-88.
20. Smith JK, Mamoon NM, Duhe RJ: Emerging Roles of Targeted Small Molecule Protein-Tyrosine Kinase Inhibitors in Cancer Therapy. Oncology Research 2004, 14:175-225.
21. Rodems SM, Hamman BD, Lin C, Zhao J, Shah S, Heidary D, Makings L, Stack JH, Pollok BA: A FRET-based assay platform for ultra-high density drug screening of protein kinases and phosphatases. Assay Drug Dev Technol 2002, 1:9-19.
22. Gazit A, Yaish P, Gilon C, Levitzki A: Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. J Med Chem 1989, 32:2344-52.
23. Sebolt-Leopold JS, Herrera R: Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004, 4:937-47.
24. Melnikova I, Golden J: Targeted protein kinases. Nature Rev. Drug Disc 2004, 3:993-994.
25. Kim JA: Targeted therapies for the treatment of cancer. Am. J. Surg. 2003, 186:264-268.
26. Vlahovic G, Crawford J: Activation of tyrosine kinases in cancer. The Oncologist 2003, 8:531-538.
27. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352:786-92.
28. Gumireddy K, Baker SJ, Cosenza SC, John P, Kang AD, Robell KA, Reddy MV, Reddy EP: A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci U S A 2005, 102:1992-7.
29. O'Hare T, Walters DK, Deininger MW, Druker BJ: AMN107: tightening the grip of imatinib. Cancer Cell 2005, 7:117-9.
30. De Clercq E: Emerging anti-HIV drugs. Expert Opin Emerg Drugs 2005, 10:241-73.
31. Study JJ: HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. J Neurooncol 2005, 74:77-86.
32. Bell IM, Stirdivant SM, Ahern J, Culberson JC, Darke PL, Dinsmore CJ, Drakas RA, Gallicchio SN, Graham SL, Heimbrook DC, Hall DL, Hau J, Kett NR, Kim AS, Kornienko M, Kuo LC, Munshi SK, Quigley AG, Reid JC, Trotter BW, Waxman LH, Williams TM, Zartman CB: Biochemical and structural characterization of a novel class of inhibitors of the type 1 insulin-like growth factor and insulin receptor kinases. Biochemistry 2005, 44:9430-40.
33. Poh TW, Pervaiz S: LY294002 and LY303511 sensitize tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production independent of the phosphoinositide 3-kinase-Akt pathway. Cancer Res 2005, 65:6264-74.
34. Bianco R, Troiani T, Tortora G, Ciardiello F: Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy. Endocr Relat Cancer 2005, 12:S159-S171.